Back Bay Life Science Advisors
Market Insights
Investment Banking Analytics Strategic Advisory
Company Global Partnerships Meet Our Team Careers Resource Library Locations
DNB//Back Bay Partnership DNB//Back Bay Healthcare Team
Corporate Contact Toronto Office
OUR SERVICES Investment Banking Analytics Strategic Advisory About Company Global Partnerships Meet Our Team Careers Resource Library Locations Market Insights DNB//BACK BAY DNB//Back Bay Partnership DNB//Back Bay Healthcare Team Contact Corporate Contact Toronto Office
Back Bay Life Science Advisors
The Year of US-Nordic Collaboration

2022 was the year of US-Nordic Collaboration for Back Bay Life Science Advisors

Read More
BlogBack Bay Life Science AdvisorsJanuary 10, 2023Jonathan Gertler
BioStock Life Science Summit Keynote (Video)

Jonathan Gertler’s keynote address at the BioStock Life Science Summit

Read More
Back Bay Life Science AdvisorsDecember 20, 2022
New Podcast with Back Bay and Nasdaq: Preparing Biopharma and Medtech Companies for Public Listing
PodcastBack Bay Life Science AdvisorsSeptember 20, 2022Mergers, Podcast, Investment Banking, Public Listing, Biotech
Versantis to be acquired by GENFIT
Press Release, Client NewsBack Bay Life Science AdvisorsSeptember 19, 2022Transactions, Diligence, Biotech, M&A
Back Bay Advised Caladrius Biosciences on Merger with Cend Therapeutics

Back Bay Life Science Advisors’ investment banking and strategy teams announced their role in the deal between Caladrius Biosciences, now called Lisata Therapeutics, and Cend Therapeutics

Read More
Back Bay Transaction NewsBack Bay Life Science AdvisorsSeptember 19, 2022Transactions, Investment Banking, Mergers
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Press Release, Client NewsBack Bay Life Science AdvisorsSeptember 15, 2022Merger, Oncology, Biopharma, Investment Banking
Inflation Reduction Act: Unprecedented Changes to Medicare Prescription Drug Pricing
Back Bay Life Science AdvisorsAugust 11, 2022
Cell and Gene Therapy in Canada - Insights Magazine
Back Bay in the NewsBack Bay Life Science AdvisorsJune 2, 2022Cell Therapy, Drug Development, Biopharma, Funding, Partnering, Canada
From Drug Target Inhibition to Degradation: a TACtical Strategy - Nature Biopharma Dealmakers
Back Bay in the NewsBack Bay Life Science AdvisorsJune 2, 2022IPOs, VC, Drug Development, Investment Banking
Inefficient Markets: Public Market Dislocations and Negative Biotech Enterprise Values
BlogInvestment Banking TeamMay 31, 2022BioPharma, IPO, Investing
Biopharma Companies Don’t Need to Be Public to Survive
BlogInvestment Banking TeamApril 14, 2022BioPharma, IPO, Investing
A Paradigm Shift in Medical Technology
Investment Banking UpdateInvestment Banking TeamMarch 14, 2022Investment, Medtech, Digital Health, Healthtech
Back Bay Associate Named Consulting Magazine’s Rising Star for Excellence in Financial Consulting
Back Bay in the News, Awards and RankingsInvestment Banking TeamFebruary 28, 2022Investment Banking, Consulting Awards
Back Bay Life Science Advisors Ranked Among Best Boutique Consulting Firms

Back Bay ranked Top Boutique Consulting Firm 2022

Read More
Awards and RankingsBack Bay Life Science AdvisorsFebruary 15, 2022Best Consulting Firm Ranking, Life Science Jobs
Back Bay in Cell & Gene: Shining Light on the Commercial Potential of Optogenetic Therapies

Back Bay Life Science Advisors examines the commercial and clinical potential of optogenetic therapies from ophthalmology diseases, and oncology to chronic pain and more.

Read More
BlogBack Bay Life Science AdvisorsFebruary 3, 2022Neurology, Optogenetics, Oncology
With Biotech Public Valuations Down, Look to Alternative Strategies to Enhance Company Value
BlogBack Bay Life Science AdvisorsJanuary 31, 2022Valuation, Investment, M&A, Investment Banking
Back Bay in Wall Street Journal, Pro Venture Capital: Medical-Device IPOs, Acquisitions Jumped in 2021
Media CoverageBack Bay Life Science AdvisorsJanuary 15, 2022Investing, Medical Device, IPOs, M&A
Trends, Opportunities, and Outlooks for Investment in the US Biotech Market
WebinarBack Bay Life Science AdvisorsJanuary 4, 2022Biotech, Biotech Investment, Canada
Investment Banking Spotlight: GE, Johnson & Johnson, Philips, Siemens: Restructurings = Accelerating Focus and Investment
BlogInvestment Banking TeamDecember 14, 2021Investment Banking, Restructuring, Life Science Financing
Outsourced Pharma: The Pharmacological Treatment Pipeline For Traumatic Brain Injury
BlogBack Bay Life Science AdvisorsDecember 13, 2021Pharmaceutical Development, Neurology, Drug Pipeline, FDA
Newer Older
 

545 Boylston Street
12th Floor
Boston, MA 02116

+1 617.236.0954 Office
+1 617.236.1215 Fax

Boston | Toronto

 

OUR SERVICES

STRATEGIC ADVISORY >>

  • Life sciences corporate growth and market access strategy

  • Franchise, business unit & therapeutic area strategy

  • Competitive intelligence

  • Asset & development prioritization

  • Platform implementation

  • Payor/Pricing strategy

  • Contracting strategy

  • Launch & counter-launch strategy

  • Product positioning, branding & messaging

  • Life-cycle management

  • Corporate growth strategy

  • Liquidity & exit planning

INVESTMENT BANKING >>

FINANCING >>

  • Mergers, acquisitions & divestitures

  • IPO preparedness and execution

  • Private & public company, cross-border execution

  • Financing support

  • Fairness opinion, valuation

  • Treasury solutions

  • Fixed income origination

  • Equity capital markets

  • Liquidity and exit planning

  • Due diligence and valuation

  • Divestments

  • Licensing (buy and sell side)

  • Partnering

  • Recapitalization

  • New Company formation

  • Investment Grade Bonds

  • High yield and convertible bonds

  • Debt and restructuring

Subscribe

Sign up with your email address to receive weekly market updates.

We respect your privacy.

Thank you for subscribing.

©2025 Back Bay Life Science Advisors | Privacy Policy